Gilead Is UBS's Top Biotechnology Pick, Roden Says

Sept. 10 (Bloomberg) -- Matthew Roden, senior biotechnology analyst at UBS Securities, talks with Bloomberg Industries senior health-care analyst Andrew Berens and Bloomberg First Word health-care journalist Sasha Damouni about the Hepatitis C marketplace including drug development and potential mergers and acquisitions in the space. (Source: Bloomberg)

Full Show: Bloomberg Businessweek (03/24)
38:01 - Bloomberg Television takes you behind the scenes of our award-winning magazine "Bloomberg Businessweek." Hosts Carol Massar and Oliver Renick talk with the writers who break news on a weekly basis. (Source: Bloomberg)
  • S&P 500 Winners and Losers for 03/24
  • Full Show: Best of Bloomberg Markets Middle East (03/24)
  • How to Trade the Health Care Select Sector SPDR Fund